Listed

PharmaCyte Biotech, Inc.: Form 10-Q for the period ended Oct 31, 2016

Filed with the SEC on Dec 2, 2016 and accepted by EDGAR at Dec 2, 2016, 17:26 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2016-10-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2016-08-01 to 2016-10-31$0us-gaap:Revenues
Revenue6 months2016-05-01 to 2016-10-31$0us-gaap:Revenues
Cost of revenue3 months2016-08-01 to 2016-10-31$0us-gaap:CostOfRevenue
Cost of revenue6 months2016-05-01 to 2016-10-31$0us-gaap:CostOfRevenue
Gross profit3 months2016-08-01 to 2016-10-31$0us-gaap:GrossProfit
Gross profit6 months2016-05-01 to 2016-10-31$0us-gaap:GrossProfit
Research and development3 months2016-08-01 to 2016-10-31$253.8kus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2016-05-01 to 2016-10-31$428.8kus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2016-08-01 to 2016-10-31−$974.2kus-gaap:OperatingIncomeLoss
Operating income6 months2016-05-01 to 2016-10-31−$2.0mus-gaap:OperatingIncomeLoss
Interest expense3 months2016-08-01 to 2016-10-31$356us-gaap:InterestExpense
Interest expense6 months2016-05-01 to 2016-10-31$925us-gaap:InterestExpense
Net income3 months2016-08-01 to 2016-10-31−$974.6kus-gaap:NetIncomeLoss
Net income6 months2016-05-01 to 2016-10-31−$2.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2016-08-01 to 2016-10-31$0.00us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS6 months2016-05-01 to 2016-10-31$0.00us-gaap:EarningsPerShareBasicAndDiluted
Diluted shares (weighted)3 months2016-08-01 to 2016-10-31848,910,100 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2016-05-01 to 2016-10-31818,540,900 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Cash and equivalentsAt period end2016-10-31$1.6mus-gaap:Cash
Current assetsAt period end2016-10-31$1.6mus-gaap:AssetsCurrent
Total assetsAt period end2016-10-31$6.7mus-gaap:Assets
Current liabilitiesAt period end2016-10-31$449.0kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2016-10-31$449.0kus-gaap:Liabilities
Shareholders' equityAt period end2016-10-31$6.3mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001683168-16-000848. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.